Polymyalgia rheumatica

Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica

Retrieved on: 
Tuesday, September 12, 2023

Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!

Key Points: 
  • Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!
  • Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
  • For the rheumatology program, a fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference

Retrieved on: 
Thursday, June 8, 2023

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .

Key Points: 
  • Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .
  • The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.
  • Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
  • To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com .

Sparrow Pharmaceuticals Presents ePoster on SPI-62 at the 25th European Congress of Endocrinology

Retrieved on: 
Saturday, May 13, 2023

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented an ePoster on its lead candidate and HSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).

Key Points: 
  • Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented an ePoster on its lead candidate and HSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).
  • “We highlight that, unlike current treatments for Cushing’s syndrome, HSD-1 inhibitors such as SPI-62 might not be expected to carry risk of adrenal crisis,” said Frank Czerwiec, M.D., Ph.D, Chief Medical Officer at Sparrow Pharmaceuticals and ePoster presenter.
  • Even with complete HSD-1 inhibition, though, circulating cortisol can diffuse into cells in amounts sufficient to maintain life-critical functions such as stress response.
  • To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com .

Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort

Retrieved on: 
Wednesday, March 8, 2023

“This trial is expected to teach us whether SPI-62 can separate the desired and undesired effects of prednisolone,” said David Katz, PhD, Chief Scientific Officer of Sparrow.

Key Points: 
  • “This trial is expected to teach us whether SPI-62 can separate the desired and undesired effects of prednisolone,” said David Katz, PhD, Chief Scientific Officer of Sparrow.
  • Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
  • For the PMR trial a fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Retrieved on: 
Wednesday, March 1, 2023

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

Key Points: 
  • "Polymyalgia rheumatica can be an incapacitating disease, causing painful disease flares in multiple parts of the body that leave people fatigued and unable to fully perform everyday activities.
  • Kevzara was previously approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
  • Patients often experience flares during tapering of, or relapse after discontinuation of corticosteroid (CS) treatment.
  • Patients with PMR report difficulty in carrying out everyday functions such as getting out of bed, standing up from a chair, or lifting their arms.

Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022

Retrieved on: 
Sunday, November 13, 2022

Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting.

Key Points: 
  • Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting.
  • The effects of long-term use can be severe, including diabetes, cardiovascular disease, and muscle and skin atrophy.
  • An effective glucocorticoid with fewer side effects would be a breakthrough for them, said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals.
  • The study data presented at ACR demonstrate that SPI-62 can prevent cardiometabolic, muscular, and dermal adverse side effects of CORT in mouse.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica

Retrieved on: 
Friday, September 9, 2022

This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.

Key Points: 
  • This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.
  • If we observe separation of the desired from undesired effects of prednisolone, well be an important step closer to solving a decades-old puzzle in autoimmune disease treatment.
  • Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting

Retrieved on: 
Tuesday, June 14, 2022

Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.

Key Points: 
  • Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.
  • In fact, studies have shown that UFC normalization doesnt correlate with clinical endpoints in patients with Cushings syndrome.
  • The study analyzed historical clinical trial data to better characterize how SPI-62 impacts cortisol levels and the bodys homeostatic response to those changes.
  • To learn more about Sparrow Pharmaceuticals and its clinical pipeline, visit the website at www.sparrowpharma.com .

Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology

Retrieved on: 
Saturday, June 4, 2022

Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica at the 2022 Annual European Congress of Rheumatology (EULAR 2022).

Key Points: 
  • Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica at the 2022 Annual European Congress of Rheumatology (EULAR 2022).
  • Researchers studied the ability of Sparrows therapeutic candidate SPI-62, a HSD-1 inhibitor, to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse.
  • SPI-47, a fixed-dose-combination of SPI-62 and prednisolone, is in clinical development for autoimmune and inflammatory diseases.
  • An effective glucocorticoid with fewer side effects would be a boon for patients, said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals.

Sparrow Pharmaceuticals to Present New Pharmacology Data on SPI-62 at the 2022 Annual European Congress of Rheumatology

Retrieved on: 
Wednesday, June 1, 2022

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new pharmacology data at the 2022 Annual European Congress of Rheumatology (EULAR) on its lead candidate, SPI-62, an HSD-1 inhibitor.

Key Points: 
  • Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new pharmacology data at the 2022 Annual European Congress of Rheumatology (EULAR) on its lead candidate, SPI-62, an HSD-1 inhibitor.
  • SPI-47, a fixed-dose-combination of SPI-62 and prednisolone, is being developed for autoimmune and inflammatory diseases beginning with polymyalgia rheumatica.
  • Sparrow will present the data during an in-person poster session.
  • EULAR 2022 will take place 1-4 June 2022, at the Bella Center Copenhagen in Copenhagen, Denmark.